1 asset in Severe Combined Immunodeficiency Due To DCLRE1C Deficiency

Therapeutic assets addressing Severe Combined Immunodeficiency Due To DCLRE1C Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Artegene Drug Product Severe Combined Immunodeficiency Due To DCLRE1C Deficiency	Assistance Publique - Hôpitaux de Paris	P1/2	NR ()